Xencor Inc. (CH:XE9)
NASDAQ:XE9
XE9 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Proprietary Antibody Engineering PlatformXencor's core XmAb/Xtend engineering capabilities are durable competitive assets that drive differentiated biologics across oncology and immunology. A reusable platform raises probability of multiple successful programs and recurring partner licensing, supporting steady long-term technology value beyond any single program.
Manageable Leverage / Balance Sheet FlexibilityLow debt-to-equity (~0.13) provides financing flexibility to fund R&D and absorb clinical development timing. With modest leverage, Xencor can access debt or equity markets without extreme balance-sheet strain, which materially reduces the risk of immediate solvency pressure while advancing pipelines.
Progress In TL1A Autoimmune / IBD FranchiseClinical advancement of TL1A franchise (XmAb942, XmAb412) creates a clear mid‑term commercialization pathway into a multibillion-dollar IBD market. Positive Phase 1 data and scheduled Phase 2b/FIH studies underpin a structural growth opportunity if readouts validate efficacy and differentiation versus first‑generation biologics.
Bears Say
Declining Revenue And Deep LossesA sustained drop in trailing revenue combined with very large net losses indicates the business has not yet converted R&D into recurring commercial revenue. Over the medium term, persistent operating losses erode reserves and constrain reinvestment unless offset by successful program monetization or new collaboration cash inflows.
Negative Free Cash Flow / Cash BurnMaterial negative operating and free cash flow signals ongoing cash burn driven by development spending. Even with some improvement, continued negative FCF increases the likelihood of future financing, dilution, or partnership-driven funding, raising structural execution and governance risks over the next several quarters.
Partnership Concentration And Recent Collaboration HeadwindsRevenue model relies on upfronts, milestones and royalties from partners, which are lumpy and partner-dependent. Recent collaboration termination and royalty disputes reduce expected cashflows and highlight counterparty risk that can materially alter long-term revenue visibility and strategic optionality.
Xencor News
XE9 FAQ
What was Xencor Inc.’s price range in the past 12 months?
Currently, no data Available
What is Xencor Inc.’s market cap?
Xencor Inc.’s market cap is CHF730.89M.
When is Xencor Inc.’s upcoming earnings report date?
Xencor Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 51 days.
How were Xencor Inc.’s earnings last quarter?
Xencor Inc. released its earnings results on May 06, 2026. The company reported -$1.367 earnings per share for the quarter, missing the consensus estimate of -$0.663 by -$0.704.
Is Xencor Inc. overvalued?
According to Wall Street analysts Xencor Inc.’s price is currently Undervalued.
Does Xencor Inc. pay dividends?
Xencor Inc. does not currently pay dividends.
What is Xencor Inc.’s EPS estimate?
Xencor Inc.’s EPS estimate is -0.64.
How many shares outstanding does Xencor Inc. have?
Currently, no data Available
What happened to Xencor Inc.’s price movement after its last earnings report?
Xencor Inc. reported an EPS of -$1.367 in its last earnings report, missing expectations of -$0.663. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Xencor Inc.?
Currently, no hedge funds are holding shares in CH:XE9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xencor Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF19.38 (― Downside)
CHF19.38 (― Downside)
Insider Transactions
Sold Shares
Worth CHF34.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.75%
12-Months-Change
Fundamentals
Return on Equity
-28.77%
Trailing 12-Months
Asset Growth
-18.55%
Trailing 12-Months
Company Description
Xencor Inc.
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
XE9 Stock 12 Month Forecast
Average Price Target
$19.38
Dianthus Therapeutics
―
Autolus Therapeutics
―
Stoke Therapeutics
―
Relay Therapeutics
―
Maravai Lifesciences Holdings
―
Options Prices
Currently, No data available
---